Literature DB >> 9842903

MAdCAM-1 costimulates T cell proliferation exclusively through integrin alpha4beta7, whereas VCAM-1 and CS-1 peptide use alpha4beta1: evidence for "remote" costimulation and induction of hyperresponsiveness to B7 molecules.

K Lehnert1, C G Print, Y Yang, G W Krissansen.   

Abstract

We have analyzed the effects of the alpha4 integrin ligands mucosal addressin cell adhesion molecule-1 (MAdCAM-1), vascular cell adhesion molecule-1 (VCAM-1), and the fibronectin CS-1 splice variant on T cell activation. Immobilized MAdCAM-1 and VCAM-1 IgG-Fc chimeras and a fibronectin CS-1 peptide efficiently costimulate T cell proliferation when antigen presentation is mimicked by anti-CD3 antibody. VCAM-1-Fc and fibronectin CS-1, which are adhesive ligands for both the alpha4beta1 and alpha4beta7 integrins, medicate T cell costimulation exclusively through integrin alpha4beta1, but not through alpha4beta7. The inability of VCAM-1-Fc to costimulate via alpha4beta7 suggests that cell adhesion per se is insufficient, and that exquisite recognition and activation events must be triggered. MAdCAM-1-Fc mediates costimulation exclusively via alpha4beta7, and can both synergize with and induce hyperresponsiveness to the classical costimulator B7-2. MAdCAM-1-Fc and VCAM-1-Fc, but not B7-2, effectively costimulate when immobilized on sites spatially distant from the anti-CD3 antibody ("remote" costimulation). In vitro, the relative potencies of the CAM were VCAM-1-Fc> ICAM-1-Fc> MAdCAM-1-Fc > B7-Fc, except at high concentrations where ICAM-1 was the most potent. Features of costimulatory CAM revealed by this study have important implications for the design of immunotherapeutic vaccine strategies to combat cancer and infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9842903     DOI: 10.1002/(SICI)1521-4141(199811)28:11<3605::AID-IMMU3605>3.0.CO;2-J

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  12 in total

1.  Anti-adhesion molecule therapy for inflammatory bowel disease.

Authors:  Subrata Ghosh; Remo Panaccione
Journal:  Therap Adv Gastroenterol       Date:  2010-07       Impact factor: 4.409

2.  The V2 loop of HIV gp120 delivers costimulatory signals to CD4+ T cells through Integrin α4β7 and promotes cellular activation and infection.

Authors:  Livia R Goes; Alia Sajani; Aida Sivro; Ronke Olowojesiku; Jocelyn C Ray; Ian Perrone; Jason Yolitz; Alexandre Girard; Louise Leyre; Constantinos Kurt Wibmer; Lynn Morris; Giacomo Gorini; Genoveffa Franchini; Rosemarie D Mason; Mario Roederer; Saurabh Mehandru; Marcelo A Soares; Claudia Cicala; Anthony S Fauci; James Arthos
Journal:  Proc Natl Acad Sci U S A       Date:  2020-12-07       Impact factor: 11.205

Review 3.  Role of beta7 integrins in intestinal lymphocyte homing and retention.

Authors:  G Gorfu; J Rivera-Nieves; K Ley
Journal:  Curr Mol Med       Date:  2009-09       Impact factor: 2.222

4.  Integrin α4β7 Blockade Preferentially Impacts CCR6+ Lymphocyte Subsets in Blood and Mucosal Tissues of Naive Rhesus Macaques.

Authors:  Giulia Calenda; Rassamon Keawvichit; Géraldine Arrode-Brusés; Kovit Pattanapanyasat; Ines Frank; Siddappa N Byrareddy; James Arthos; Claudia Cicala; Brooke Grasperge; James L Blanchard; Agegnehu Gettie; Keith A Reimann; Aftab A Ansari; Elena Martinelli
Journal:  J Immunol       Date:  2017-12-01       Impact factor: 5.422

5.  Energy landscape differences among integrins establish the framework for understanding activation.

Authors:  Jing Li; Timothy A Springer
Journal:  J Cell Biol       Date:  2017-11-09       Impact factor: 10.539

6.  Cadherin 26 is an alpha integrin-binding epithelial receptor regulated during allergic inflammation.

Authors:  J M Caldwell; M H Collins; K A Kemme; J D Sherrill; T Wen; M Rochman; E M Stucke; L Amin; H Tai; P E Putnam; M J Jiménez-Dalmaroni; M R Wormald; A Porollo; J P Abonia; M E Rothenberg
Journal:  Mucosal Immunol       Date:  2017-01-04       Impact factor: 7.313

7.  MAdCAM costimulation through Integrin-α4β7 promotes HIV replication.

Authors:  Fatima Nawaz; Livia R Goes; Jocelyn C Ray; Ronke Olowojesiku; Alia Sajani; Aftab A Ansari; Ian Perrone; Joseph Hiatt; Donald Van Ryk; Danlan Wei; Mia Waliszewski; Marcelo A Soares; Katija Jelicic; Mark Connors; Stephen A Migueles; Elena Martinelli; Francois Villinger; Claudia Cicala; Anthony S Fauci; James Arthos
Journal:  Mucosal Immunol       Date:  2018-06-06       Impact factor: 7.313

8.  Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to α4β7.

Authors:  Sakaorat Lertjuthaporn; Claudia Cicala; Donald Van Ryk; Matthew Liu; Jason Yolitz; Danlan Wei; Fatima Nawaz; Allison Doyle; Brooke Horowitch; Chung Park; Shan Lu; Yang Lou; Shixia Wang; Ruimin Pan; Xunqing Jiang; Francois Villinger; Siddappa N Byrareddy; Philip J Santangelo; Lynn Morris; Constantinos Kurt Wibmer; Kristin Biris; Rosemarie D Mason; Jason Gorman; Joseph Hiatt; Elena Martinelli; Mario Roederer; Dai Fujikawa; Giacomo Gorini; Genoveffa Franchini; Anush Arakelyan; Aftab A Ansari; Kovit Pattanapanyasat; Xiang-Peng Kong; Anthony S Fauci; James Arthos
Journal:  PLoS Pathog       Date:  2018-08-28       Impact factor: 6.823

9.  The HIV-1 envelope protein gp120 impairs B cell proliferation by inducing TGF-β1 production and FcRL4 expression.

Authors:  Katija Jelicic; Raffaello Cimbro; Fatima Nawaz; Da Wei Huang; Xin Zheng; Jun Yang; Richard A Lempicki; Massimiliano Pascuccio; Donald Van Ryk; Catherine Schwing; Joseph Hiatt; Noreen Okwara; Danlan Wei; Gregg Roby; Antonio David; Ii Young Hwang; John H Kehrl; James Arthos; Claudia Cicala; Anthony S Fauci
Journal:  Nat Immunol       Date:  2013-10-27       Impact factor: 25.606

10.  Early treatment of SIV+ macaques with an α4β7 mAb alters virus distribution and preserves CD4+ T cells in later stages of infection.

Authors:  P J Santangelo; C Cicala; S N Byrareddy; K T Ortiz; D Little; K E Lindsay; S Gumber; J J Hong; K Jelicic; K A Rogers; C Zurla; F Villinger; A A Ansari; A S Fauci; J Arthos
Journal:  Mucosal Immunol       Date:  2017-12-20       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.